Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256255 | 0.88 | CALCRL (0.51) | CALCRLKMT2ASMN1; SMN2C5AR1KDM4E | |
| SCHEMBL12362443 | 0.86 | KMT2A (0.54) | CALCRLKMT2ASMN1; SMN2C5AR1KDM4E | |
| SCHEMBL12362445 | 0.83 | KMT2A (0.54) | CALCRLKMT2ASMN1; SMN2C5AR1GRIN1 | |
| SCHEMBL12048967 | 0.82 | CALCRL (0.44) | CALCRLKMT2ASMN1; SMN2C5AR1KDM4E | |
| SCHEMBL2254681 | 0.76 | CALCRL (0.44) | CALCRLKMT2ASMN1; SMN2C5AR1GRIN1 | |
| SCHEMBL4309342 | 0.72 | GRIN1 (0.42) | CALCRLKMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12362442 | 0.72 | KMT2A (0.53) | CALCRLKMT2ASMN1; SMN2C5AR1KDM4E | |
| SCHEMBL14198765 | 0.70 | KMT2A (0.58) | CALCRLKMT2ASMN1; SMN2C5AR1KDM4E | |
| SCHEMBL2256984 | 0.69 | CALCRL (0.52) | CALCRLKMT2ASMN1; SMN2C5AR1KDM4E | |
| SCHEMBL12362418 | 0.69 | KMT2A (0.57) | CALCRLKMT2ASMN1; SMN2C5AR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071772-B2 | Spirolactam bicyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | CALCRL 2/4885KMT2A 4316/4885SMN1; SMN2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.